Drug
Ctx460
Ctx460: highest development phase Phase 1/2, developed by CRISPR Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- CRISPR Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| CTX460 NCT07850076 | Phase 1/2 | Alpha-1 Antitrypsin Deficiency (AATD) |
Latest
No recent events.
Follow Ctx460 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.